Document Type : Original Article
Authors
1
Professor of Pediatrics Department, Faculty of Medicine, Zagazig university, Egypt
2
Professor of Clinical Pathology Department, Faculty of Medicine, Zagazig University, Egypt
3
Pediatrics Department, Faculty of Medicine, Zagazig University, Egypt
4
Assistant professor of Pediatrics Department, Faculty of Medicine, Zagazig university, Egypt
Abstract
Background: Patients with cardiovascular disease, lupus nephritis, idiopathic immunoglobulin A nephropathy, and renal failure may benefit from omega-3 fatty acids via changing the shape and function of cell membranes and the synthesis of lipid mediators such eicosanoids. This study aimed to evaluate the role of omega-3 fatty acids supplementation in minimizing and prevention of cardiovascular disorders in children with chronic kidney disease. Methods: This clinical trial investigation, which was carried out in the pediatric nephrology section of the pediatric department at Zagazig University, involved twenty pediatric patients with chronic kidney disease (CKD) undergoing hemodialysis. All patients received 1000mg of omega-3 polyunsaturated fatty acids (ω-3PUFAs) daily. Before and after the trial, blood samples were taken from the patients to evaluate hemoglobin, ferritin, triglycerides, total cholesterol, LDL cholesterol, and C-reactive protein. Results: 20 patients, 11 males and 9 females, mean age (13.9±2.1) (11–18y). There was significant decrease in CRP levels (median from 6.2 to 1.3, p<0.001), total cholesterol decreased by a median of 16.9%, triglycerides by 20.4%, and LDL cholesterol by 15.3%, while HDL cholesterol increased by 10.76%(p<0.001) and clinically meaningful. 100% of patients showed improvements in total cholesterol and triglycerides, while 90% showed improvements in LDL cholesterol. A significant improvement in CHD risk classification, with the proportion of patients in the lowest risk category (class 1) increasing from 20% to 65% after supplementation. Conclusion: that omega-3 supplementation could be a valuable therapeutic intervention in pediatric CKD patients, offering benefits across multiple parameters including inflammation, lipid profile, and cardiovascular risk.
Keywords
Main Subjects
)
View on SCiNiTO